Open AccessSerum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
Author(s) -
Weijie Cao,
Yiting Xu,
Yun Shen,
Yufei Wang,
Xiaojing Ma,
Yuqian Bao
Publication year - 2021
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s328206
Subject(s) - odds ratio , fatty liver , fgf21 , medicine , confounding , confidence interval , diabetes mellitus , endocrinology , gastroenterology , disease , fibroblast growth factor , receptor
Although fibroblast growth factor-23 (FGF23) is involved in the development of metabolic diseases, its association with metabolic-associated fatty liver disease (MAFLD) remains unknown. We explored the relationship between serum fibroblast growth factor-23 level, metabolic associated fatty liver disease, and liver fat content.